Vandenplas Yvan, De Greef Elisabeth, Hauser Bruno
Department of Pediatrics, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium,
Eur J Pediatr. 2014 Sep;173(9):1209-16. doi: 10.1007/s00431-014-2308-4. Epub 2014 Apr 12.
Guidelines recommend the use of extensively hydrolyzed cow's milk protein-based formulas (eHF) in the treatment of infants with cow's milk protein allergy (CMPA). Extensively hydrolyzed rice protein infant formula (eRHF) has recently become available and could offer a valid alternative. A prospective trial was performed to evaluate the hypo-allergenicity and safety of a new eRHF in infants with a confirmed CMPA. Patients were fed the study formula for 6 months. Clinical tolerance of the eRHF was evaluated with a symptom-based score (SBS) and growth (weight and length) was monitored. Forty infants (mean age, 3.4 months; range, 1-6 months) with CMPA confirmed by a food challenge were enrolled. All infants tolerated the eRHF and the SBS significantly decreased as of the first month of intervention. Moreover, the eRHF allowed a catch-up to normal weight gain as of the first month as well as a normalization of the weight-for-age, weight-for length, and BMI z-scores within the 6-month study period.
In accordance with current guidelines, this eRHF was tolerated by more than 90 % of children with proven CMPA with a 95 % confidence interval. This eRHF is an adequate and safe alternative to cow milk-based eHF.
指南推荐使用深度水解牛奶蛋白配方奶粉（eHF）治疗牛奶蛋白过敏（CMPA）婴儿。深度水解大米蛋白婴儿配方奶粉（eRHF）最近已上市，可能是一种有效的替代选择。进行了一项前瞻性试验，以评估一种新型eRHF对确诊为CMPA婴儿的低过敏性和安全性。患者食用研究配方奶粉6个月。通过基于症状的评分（SBS）评估eRHF的临床耐受性，并监测生长情况（体重和身长）。纳入了40名经食物激发试验确诊为CMPA的婴儿（平均年龄3.4个月；范围1 - 6个月）。所有婴儿均耐受eRHF，干预第一个月起SBS显著下降。此外，eRHF使婴儿从第一个月起体重追赶至正常增长，且在6个月的研究期内年龄别体重、身长别体重和BMI z评分均恢复正常。
根据现行指南，超过90%经证实的CMPA儿童耐受这种eRHF，置信区间为95%。这种eRHF是基于牛奶的eHF的一种合适且安全的替代品。
